重组活化凝血因子VII对点征阳性急性脑出血血肿扩大的影响:SPOTLIGHT与STOP-IT随机临床试验
该研究纳入69例点征阳性急性自发性脑出血患者,随机接受rFVIIa 80 μg/kg或安慰剂治疗,主要终点为24小时血肿体积扩大。结果两组血肿扩大无显著差异,90天死亡或严重残疾也无显著差异。
要点
- 点征阳性脑出血患者使用rFVIIa未显著减少24小时血肿扩大。
- 研究样本量较小,需更大规模试验验证。
核心结论
- 在点征阳性脑出血患者中,rFVIIa未显著改善影像学或临床结局。
研究设计与样本
- 平行、研究者发起、多中心、双盲、安慰剂对照随机临床试验,在加拿大(SPOTLIGHT)和美国(STOP-IT)进行,采用统一方案和预设的个体患者水平汇总分析。
- 共纳入69例急性原发性自发性脑出血且CT血管造影显示点征的患者,随机接受rFVIIa 80 μg/kg静脉注射或安慰剂,在卒中发作后6.5小时内尽快给药。
主要发现
- rFVIIa组基线脑出血体积中位数(IQR)为16.3(9.6-39.2)mL,安慰剂组为20.4(8.6-32.6)mL。
- rFVIIa组24小时脑出血体积增加中位数(IQR)为2.5(0-10.2)mL,安慰剂组为2.6(0-6.6)mL。
- 调整基线体积、治疗时间及试验后,两组脑出血扩大或总出血扩大无差异。
临床怎么用
- 对于点征阳性急性脑出血患者,rFVIIa不推荐用于减少血肿扩大或改善临床结局。
局限性
- 样本量较小(69例),可能不足以检测出微小差异。
- 研究仅纳入点征阳性患者,结果不能推广至所有脑出血患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intracerebral hemorrhage (ICH) is a devastating stroke type that lacks effective treatments. An imaging biomarker of ICH expansion-the computed tomography (CT) angiography spot sign-may identify a subgroup that could benefit from hemostatic therapy. OBJECTIVE: To investigate whether recombinant activated coagulation factor VII (rFVIIa) reduces hemorrhage expansion among patients with spot sign-positive ICH. DESIGN, SETTING, AND PARTICIPANTS: In parallel investigator-initiated, multicenter, double-blind, placebo-controlled randomized clinical trials in Canada ("Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy [SPOTLIGHT]) and the United States (The Spot Sign for Predicting and Treating ICH Growth Study [STOP-IT]) with harmonized protocols and a preplanned individual patient-level pooled analysis, patients presenting to the emergency department with an acute primary spontaneous ICH and a spot sign on CT angiography were recruited. Data were collected from November 2010 to May 2016. Data were analyzed from November 2016 to May 2017. INTERVENTIONS: Eligible patients were randomly assigned 80 μg/kg of intravenous rFVIIa or placebo as soon as possible within 6.5 hours of stroke onset. MAIN OUTCOMES AND MEASURES: Head CT at 24 hours assessed parenchymal ICH volume expansion from baseline (primary outcome) and total (ie, parenchymal plus intraventricular) hemorrhage volume expansion (secondary outcome). The pooled analysis compared hemorrhage expansion between groups by analyzing 24-hour volumes in a linear regression model adjusted for baseline volumes, time from stroke onset to treatment, and trial. RESULTS: Of the 69 included patients, 35 (51%) were male, and the median (interquartile range [IQR]) age was 70 (59-80) years. Baseline median (IQR) ICH volumes were 16.3 (9.6-39.2) mL in the rFVIIa group and 20.4 (8.6-32.6) mL in the placebo group. Median (IQR) time from CT to treatment was 71 (57-96) minutes, and the median (IQR) time from stroke onset to treatment was 178 (138-197) minutes. The median (IQR) increase in ICH volume from baseline to 24 hours was small in both the rFVIIa group (2.5 [0-10.2] mL) and placebo group (2.6 [0-6.6] mL). After adjustment, there was no difference between groups on measures of ICH or total hemorrhage expansion. At 90 days, 9 of 30 patients in the rFVIIa group and 13 of 34 in the placebo group had died or were severely disabled (P = .60). CONCLUSIONS AND RELEVANCE: Among patients with spot sign-positive ICH treated a median of about 3 hours from stroke onset, rFVIIa did not significantly improve radiographic or clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01359202 and NCT00810888.
引用
- Gladstone DJ, Aviv RI, Demchuk AM, et al. Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials. JAMA Neurol. 2019. PMID: 31424491. doi:10.1001/jamaneurol.2019.2636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。